Scott Schlackman Purchases 2,500 Shares of Medifast (NYSE:MED) Stock

Medifast Inc (NYSE:MED) Director Scott Schlackman acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the transaction, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. This represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Scott Schlackman also recently made the following trade(s):

• On Friday, May 8th, Scott Schlackman bought 2,500 shares of Medifast stock. The stock was purchased at an average price of $12.65 per share, for a total transaction of $31,625.00.

Medifast Price Performance

NYSE:MED traded up $0.16 on Tuesday, reaching $12.56. The stock had a trading volume of 168,560 shares, compared to its average volume of 210,108. The company has a market cap of $139.63 million, a price-to-earnings ratio of -6.86 and a beta of 0.55. The firm’s fifty day moving average is $10.66 and its two-hundred day moving average is $11.09. Medifast Inc has a 12-month low of $9.22 and a 12-month high of $15.46.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.36. The business had revenue of $76.04 million for the quarter, compared to analyst estimates of $69.20 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. As a group, research analysts forecast that Medifast Inc will post -2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Stephens lowered their price target on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, February 19th. Finally, Weiss Ratings lowered Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Medifast currently has an average rating of “Reduce” and an average price target of $12.00.

Institutional Investors Weigh In On Medifast

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its position in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the period. Quantbot Technologies LP acquired a new stake in Medifast in the 3rd quarter worth approximately $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in Medifast in the 4th quarter worth approximately $47,000. State of Wyoming acquired a new stake in Medifast in the 4th quarter worth approximately $59,000. Finally, Strs Ohio bought a new position in Medifast in the 1st quarter worth approximately $78,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.